Summary: In a post hoc analysis of the SUSTAIN 6 trial (n=1139 with type 2 diabetes and no diabetic kidney disease at baseline), semaglutide was associated with lower odds of new-onset diabetic kidney disease versus placebo (odds ratio 0.56, 95% CI 0.42 to 0.74). In the high-risk subgroup the odds ratio was 0.51 (95% CI 0.38 to 0.69) with a number needed to treat of 7, and the benefit was largely driven by changes in urinary albumin/creatinine ratio.
PICO Summary
| Element | Detail |
|---|---|
| Population | 1139 adults with type 2 diabetes and no diabetic kidney disease at baseline, drawn from the randomized, double-blind, placebo-controlled SUSTAIN 6 trial (multicentre); 952 of 1139 classified as high DKD risk using a validated prediction model. Post hoc analysis. |
| Intervention | Subcutaneous semaglutide 0.5 mg or 1.0 mg once weekly. |
| Comparison | Matching placebo once weekly. |
| Outcome | New-onset DKD (UACR ≥30 mg/g and/or eGFR <60 mL/min/1.73 m²) developed in 28.7% overall. Semaglutide versus placebo: odds ratio 0.56 (95% CI 0.42 to 0.74; p<0.0001) in the total population and 0.51 (95% CI 0.38 to 0.69; p<0.0001) in the high-risk population. Number needed to treat 7 in the high-risk group. Effect largely driven by UACR changes. As a post hoc outcome these estimates are associational and hypothesis-generating, not pre-specified efficacy. |
Semaglutide and primary prevention of diabetic kidney disease
SUSTAIN 6 post hoc · type 2 diabetes · RCT
In this SUSTAIN 6 post hoc analysis semaglutide was associated with about 44% lower odds of new-onset diabetic kidney disease, with the largest signal in high-risk patients (NNT 7). As a non-pre-specified, UACR-driven outcome it is hypothesis-generating, not a primary-prevention indication.
Expert Commentary
This post hoc analysis of SUSTAIN 6 suggests that once-weekly semaglutide may lower the odds of new-onset diabetic kidney disease in people with type 2 diabetes who have no kidney involvement at entry, with a particularly large signal in those flagged as high risk by a validated model (number needed to treat 7). The effect size is internally consistent across the total and high-risk strata, and the direction aligns with the established albuminuria-lowering action of GLP-1 receptor agonists. Several cautions temper enthusiasm. The most important limitation is that this is a post hoc analysis of a trial powered for cardiovascular outcomes, so the kidney endpoint was neither pre-specified nor randomized in its definition; the estimates are associational and hypothesis-generating rather than confirmed efficacy. The benefit was largely driven by changes in urinary albumin/creatinine ratio, a surrogate that can shift acutely and may overstate hard renal protection. The trial and analysis were supported by the manufacturer, and several authors were company employees, which warrants the usual scrutiny of an industry-sponsored secondary analysis. Can I use this with my patients? Not yet as a primary-prevention indication; the data are reassuring for a person with type 2 diabetes and high kidney risk who already needs semaglutide for glycaemia or cardiovascular benefit, but they do not justify starting it for kidney prevention alone. A pre-specified prospective trial with hard renal endpoints would be needed to settle the question.
References
Wang J, Yang J, Jiang W, Liu W, Shen Z, Gao Z, Chang B. Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: A post hoc analysis of the SUSTAIN 6 randomized controlled trial. Diabetes Obes Metab. 2024;26(11):5157-5166. doi:10.1111/dom.15860